Posted on

A push for equity + global rescheduling of psilocybin

Global Wellness Institute Announces New Initiative on Psychedelics & Healing

Major non-profit Global Wellness Institute just launched a Psychedelics & Healing Initiative with the goal of establishing evidence-based best practices, equity, and accessibility within the psychedelics industry.

The initiative brings together physicians, business innovators, research scientists, impact investors, and policy makers, including high-profile members like Rick Doblin, founder of MAPS.

The group will also advocate for the International Therapeutic Psilocybin Rescheduling Initiative, a recent movement to suspend psilocybin’s Schedule I status through the United Nations to remove research barriers across the globe.

PDF of article

Posted on

Rescheduling psilocybin GLOBALLY 🌍

Global coalition launches initiative to secure the rescheduling of psilocybin

“Given today’s scientific understanding of psilocybin’s high potential therapeutic value and low risk of dependence, a change of its status as a Schedule I drug is long overdue,” according to Christopher Koddermann.

That’s why he co-founded The International Therapeutic Psilocybin Rescheduling Initiative (ITPRI) – an initiative that’s pushing for psilocybin to be rescheduled on a global scale.

ITPRI aims to reschedule psilocybin through the United Nations’ Convention on Psychotropic Substances, which was enacted over 50 years ago 😮 This would significantly reduce the regulatory barriers that impede psilocybin research and access to treatment.

So yes, rescheduling is long overdue, but better late than never!

The UK's Leading CBD Network

PDF of article

Posted on

Progress down under

The TGA could reschedule MDMA and psilocybin — what that means for ASX-listers

Australia’s Therapeutic Goods Administration (TGA) may reschedule psilocybin and MDMA to increase access to psychedelic medicine.

After assessing several studies, the TGA recognized that the two drugs have promising therapeutic potential for treating anxiety and depression.

The substances are currently classified as Schedule 9, or “prohibited substances”, creating a barriers for conducting clinical research. The TGA is considering changing the classification to Schedule 8, or “controlled substances” (the same as THC) to allow controlled use in clinical settings. The verdict will be announced in the first week of December after an advisory committee meeting!

PDF of article

Posted on

Perpetuating the worst research blackout in scientific history

Warning UK faces ‘worst research blackout in history’ as Home Office falters on drug law

Back in May, UK Prime Minister Boris Johnson approved the rescheduling of psilocybin to make it easier to research its therapeutic effects.

Months have passed, yet the Home Office has failed to act, “perpetuating what can be considered the worst research blackout in scientific history,” according to the Conservative Drug Policy Reform Group (CDPRG).

Crispin Blunt MP, chairman of the CDPRG, is urging the Home Office to take action fast to tackle the mental health crisis. “In the 110 days that have passed since the PM’s sign off nearly 2,000 people have taken their own lives; the majority probably preventable when this research is translated into treatment,” he said.

A Home Office spokesperson said that there are currently no plans to reschedule psilocybin due to the Misuse of Drugs Regulations 2001, but they will consider any recommendations from The Advisory Council on the Misuse of Drugs (ACMD), which is reviewing the barriers to researching controlled drugs.

PDF of article

Posted on

A faster application process

Biden’s Drug Czar Wants To Make It Easier To Research Marijuana, Psychedelics And Other Schedule I Substances

Take notes Health Canada…

The Office of National Drug Control Policy (ONDCP) wants to simplify the registration process for researchers to access Schedule I drugs like psilocybin to be on par with Schedule II substances, as stated in a letter to congressional leaders.

The new registration process would skip some of the “lengthy and cumbersome” steps to encourage research into Schedule I substances. Applicants would only need to provide a general research proposal, information on storage and security of the substance, and qualifications to conduct the research.

PDF of article